44 Participants Needed

Radiofrequency Ablation for Osteoarthritis Post-Knee Replacement

(GRATKA Trial)

AS
JL
Overseen ByJennifer Laxshimalla
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: University of Calgary
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Approved in 3 JurisdictionsThis treatment is already approved in other countries

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial explores a new method to manage ongoing knee pain after knee replacement surgery. It focuses on Genicular Radiofrequency Ablation (GRFA), which uses heat to target and numb specific knee nerves. The researchers aim to determine if this method can safely and effectively reduce pain for those who haven't found relief through treatments like physical therapy or medication. Suitable candidates for this trial had knee replacement surgery over a year ago and continue to experience significant knee pain despite trying other treatments. As an unphased trial, it offers patients the opportunity to explore innovative pain management solutions when other options have failed.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. However, since the trial is for those whose pain is not relieved by conventional treatments like medication, you might be able to continue them. It's best to discuss this with the trial coordinators.

What prior data suggests that genicular radiofrequency ablation is safe for patients with failed total knee arthroplasty?

Research shows that genicular radiofrequency ablation (GRFA) is generally safe for treating knee pain. Studies have found that it effectively reduces pain in people with knee osteoarthritis. Importantly, these studies found that GRFA is well-tolerated and rarely causes serious side effects, meaning most people do not experience harmful or uncomfortable reactions.

In these studies, patients did not report major negative effects from GRFA. This is encouraging for those considering the treatment, as safety remains a top priority. While this trial will be the first to specifically test GRFA's safety in patients who still experience pain after knee replacement surgery, existing research on GRFA suggests it could be a safe option for managing knee pain.12345

Why are researchers excited about this trial?

Researchers are excited about Genicular Radiofrequency Ablation (GRFA) because it offers a novel approach to managing pain after knee replacement surgery in patients with osteoarthritis. Unlike traditional treatments such as medications or physical therapy, GRFA targets specific nerve branches directly, using heat generated by radiofrequency energy to disrupt pain signals. This method could provide longer-lasting pain relief without the systemic side effects associated with pain medications. Additionally, by precisely targeting nerves, GRFA may offer tailored pain management suited to individual anatomical differences, potentially enhancing its effectiveness.

What evidence suggests that genicular radiofrequency ablation is effective for post-knee replacement osteoarthritis?

Research has shown that genicular radiofrequency ablation (GRFA) effectively reduces knee pain for most people with osteoarthritis. GRFA uses heat to target specific nerves in the knee, helping to control pain. Many patients experience significant pain relief after this procedure. In this trial, participants will receive either GRFA or a sham procedure. GRFA has succeeded in providing pain relief and improved movement for those with chronic knee osteoarthritis who have not had surgery, as seen in previous studies. These findings suggest that GRFA could also be a promising option for those who still experience pain after knee replacement surgery.12467

Who Is on the Research Team?

AS

Ashley Smith, PhD

Principal Investigator

University of Calgary

Are You a Good Fit for This Trial?

This trial is for individuals who had knee replacement surgery at least a year ago and still experience significant pain (more than 4/10) despite treatments like physiotherapy or medication. They must have had major pain relief from a specific diagnostic nerve block. Exclusions include uncontrolled bleeding disorders, pregnancy, severe psychiatric conditions, pacemakers, certain allergies, and other specific medical issues.

Inclusion Criteria

I experienced significant pain relief from a specific nerve block procedure.
My condition did not improve with standard treatments like physiotherapy or medication.
It has been over a year since my knee replacement surgery.
See 1 more

Exclusion Criteria

Prosthetic loosening or failure, periprosthetic fracture
I have leg pain from poor blood flow when I walk.
I do not have a condition that causes uncontrolled bleeding.
See 9 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive either thermal or sham genicular radiofrequency ablation (GRFA) for knee pain management

1 day
1 visit (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment, with assessments at 3, 6, and 12 months post-GRFA

12 months
3 visits (in-person)

Crossover

Participants in the sham group are offered crossover to receive the active GRFA treatment

6 months post-treatment

What Are the Treatments Tested in This Trial?

Interventions

  • Genicular Radiofrequency Ablation
  • Sham Genicular Radiofrequency Ablation
Trial Overview The study tests Genicular Radiofrequency Ablation (GRFA), which uses heat to disrupt nerves causing knee pain after total knee arthroplasty (TKA). It's compared against a sham procedure to assess its safety and effectiveness in reducing persistent post-TKA pain using evidence-based techniques.
How Is the Trial Designed?
2Treatment groups
Experimental Treatment
Active Control
Group I: Group 1 (GRFA)Experimental Treatment1 Intervention
Group II: Group 2 (Sham)Active Control1 Intervention

Genicular Radiofrequency Ablation is already approved in United States, European Union, Canada for the following indications:

🇺🇸
Approved in United States as Genicular Radiofrequency Ablation for:
🇪🇺
Approved in European Union as Genicular Nerve Ablation for:
🇨🇦
Approved in Canada as Genicular Neurotomy for:

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Calgary

Lead Sponsor

Trials
827
Recruited
902,000+

Published Research Related to This Trial

Radiofrequency neurotomy of genicular nerves is an effective technique for reducing chronic knee pain, particularly after total knee replacement, as demonstrated in a case study of a patient with persistent pain.
The successful application of this technique in the patient's inferior right limb highlights its potential as a treatment option for managing post-surgical knee pain.
[Treatment of post-total knee replacement gonalgy by radiofrequency ablation of the genicular nerves].Sanfilippo, J., Fontaine, R., Brichant, JF.[2021]
An updated protocol for cooled genicular nerve radiofrequency ablation (RFA) has been developed to improve the targeting of sensory nerves in the knee, based on recent cadaveric studies that identified additional sensory nerves and anatomical variations.
This new protocol aims to enhance sensory denervation and potentially improve clinical outcomes for patients with chronic knee pain due to osteoarthritis, although further prospective studies are needed to validate its effectiveness and safety.
A Novel Technical Protocol for Improved Capture of the Genicular Nerves by Radiofrequency Ablation.Conger, A., Cushman, DM., Walker, K., et al.[2020]
Patients who underwent total knee arthroplasty (TKA) after genicular nerve radiofrequency ablation (GNRFA) had significantly lower odds of prolonged postoperative opioid use compared to those who had TKA alone, indicating a potential benefit in pain management.
The study found no significant differences in 2-year surgical outcomes or complication rates between the GNRFA-TKA group and the control group, suggesting that GNRFA does not increase the risk of complications when proceeding to TKA.
Total Knee Arthroplasty After Genicular Nerve Radiofrequency Ablation: Reduction in Prolonged Opioid Use Without Increased Postsurgical Complications.Stake, S., Agarwal, AR., Coombs, S., et al.[2022]

Citations

1.pubmed.ncbi.nlm.nih.govpubmed.ncbi.nlm.nih.gov/40855681/
Effectiveness of Genicular Nerve Radiofrequency Ablation ...Conclusions: GnRFA is effective in reducing knee pain in the majority of patients with osteoarthritis when large lesion techniques are used with ...
Effectiveness of genicular nerve radiofrequency ablation in ...GnRFA is effective in reducing knee pain in the majority of patients with osteoarthritis when large lesion techniques are used with moderate-certainty evidence, ...
Genicular nerve radiofrequency ablation: a systematic ...As an effective mode of pain control in the management of osteoarthritis and chronic knee pain, GNRFA is a potentially beneficial treatment ...
Genicular Radiofrequency Ablation Efficacy in Achieving ...Genicular nerve RFA has been performed in non-surgical patients with chronic knee osteoarthritis with significant post procedure improvement in pain and ...
The safety and efficacy of genicular nerve radiofrequency ...After RFA, the two groups had comparable pain relief at 3 months (p ​= ​0.06) and 6 months (p ​= ​0.20), and similar functionality at 3 months (p ​= ​0.29) and ...
Effectiveness of genicular nerve radiofrequency ablation in ...GnRFA is effective in reducing knee pain in the majority of patients with osteoarthritis when large lesion techniques are used with moderate-certainty evidence, ...
Total Knee Arthroplasty After Genicular Nerve ...Genicular nerve radiofrequency ablation-total knee arthroplasty patientshad lower odds of prolonged opioid use postoperatively (OR: 0.478; 95%: ...
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security